content

Orchard Therapeutics Announces $110M Series B Financing to Advance Transformative Gene Therapy Pipeline

Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, announced the completion of an...

Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing Sites in San Diego and Bristol

Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech...

GeNeuro To Receive โ‚ฌ12 Million Milestone Payment from Servier for Final Patient Visit in GNbAC1 CHANGE-MS Phase 2b Study

GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, such as multiple sclerosis (MS) and type...

Aptar Pharma to Exhibit Innovative Drug Delivery Devices at Pharmapack 2018 in Paris, France

Aptar Pharma, a leading drug delivery systems provider, will once again bea key exhibitor at Pharmapack 2018, Europe's dedicated pharmaceutical packaging and drug delivery...

CPhI-P-MEC India Expo 2017 Catapults the Pharma Sector to New Heights

UBM India celebrates the industry with a dazzling array of comprehensive, path-breaking events under the India Pharma Week umbrella. South...

Clinerion Joins the BlueCloud Network

HealthCarePoint (HCP), a Texas-based health care and clinical research networking-technology company founded by patient-survivors, announced its mutual collaboration with Clinerion. The...

Corbus Pharmaceuticals Initiates “RESOLVE-1” Phase 3 Study in Systemic Sclerosis

Corbus Pharmaceuticals Holdings, Inc. , a clinical stage drug development company targeting rare, serious chronic inflammatory and fibrotic diseases, announced that it has initiated...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Must read